Tourmaline Bio, Inc.
DelistedCIK 1827506fmd_0G1E3YDP81TRVC117HHTNA9Q4PManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Jun 30, 2025, 22 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Realized investment gains (losses) | – | – | 0 | 0 | 0 |
| Research and development | 15 | 34 | 18 | 32 | 67 |
| Total operating expenses | 23 | 48 | 20 | 45 | 90 |
| Operating income | (23) | (48) | (20) | (45) | (90) |
| Interest expense | – | – | – | 0 | 0 |
| Other non-operating income (expense) | – | – | 0 | 3 | 17 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Net income | (23) | (48) | (20) | (42) | (73) |